Download presentation
Presentation is loading. Please wait.
Published byPeter Floyd Modified over 5 years ago
1
Outcomes after Pancreatectomy with Routine Pasireotide Use
John W. Kunstman, MD, Debra A. Goldman, MS, Mithat Gönen, PhD, Vinod P. Balachandran, MD, FACS, Michael I. D'Angelica, MD, FACS, T Peter Kingham, MD, FACS, William R. Jarnagin, MD, FACS, Peter J. Allen, MD, FACS Journal of the American College of Surgeons Volume 228, Issue 2, Pages e2 (February 2019) DOI: /j.jamcollsurg Copyright © 2018 American College of Surgeons Terms and Conditions
2
Figure 1 Incidence of the primary end point (aggregate incidence of pancreatic fistula/leak/abscess) in the current study population routinely receiving pasireotide vs the control population that received placebo. Error bars indicate 95% CI. Journal of the American College of Surgeons , e2DOI: ( /j.jamcollsurg ) Copyright © 2018 American College of Surgeons Terms and Conditions
3
eFigure 1 Schematic of study design noting enrollment and randomization from earlier controlled trial evaluating pasireotide in patients undergoing pancreatectomy17 compared with the current study, as indicated. Journal of the American College of Surgeons , e2DOI: ( /j.jamcollsurg ) Copyright © 2018 American College of Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.